Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting
February 22, 2021 08:30 ET
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 18, 2021 08:30 ET
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells
January 04, 2021 08:00 ET
|
Pandion Therapeutics, Inc.
-Phase 1a trial achieved primary objective of safety and tolerability-PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in...
Pandion Therapeutics Appoints Katina Dorton to its Board of Directors
December 03, 2020 08:00 ET
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 16, 2020 16:01 ET
|
Pandion Therapeutics, Inc.
- Enrollment and dosing complete in Phase 1a clinical trial of PT101; top-line results expected early 2021- PT627 systemic PD-1 agonist development candidate nominated; IND-enabling studies expected...
Pandion Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
November 10, 2020 08:00 ET
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020
October 28, 2020 08:00 ET
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics to Participate in Panel Discussion at Stifel 2020 Immunology & Inflammation Virtual Summit
September 24, 2020 08:00 ET
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics to Present at Morgan Stanley Global Healthcare Conference
September 10, 2020 08:00 ET
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Reports Second Quarter 2020 Financial Results and Provides Business Update
August 31, 2020 16:05 ET
|
Pandion Therapeutics, Inc.
- Completed successful IPO providing approximately $153 million in gross proceeds; cash runway extended through first half of 2024 - Expanded executive team with appointment of John S. Sundy, M.D.,...